| Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European … BA Ference, HN Ginsberg, I Graham, KK Ray, CJ Packard, E Bruckert, ... European heart journal 38 (32), 2459-2472, 2017 | 3351 | 2017 |
| Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of … BG Nordestgaard, MJ Chapman, SE Humphries, HN Ginsberg, L Masana, ... European heart journal 34 (45), 3478-3490, 2013 | 3053 | 2013 |
| Efficacy and safety of alirocumab in reducing lipids and cardiovascular events JG Robinson, M Farnier, M Krempf, J Bergeron, G Luc, M Averna, ... New England Journal of Medicine 372 (16), 1489-1499, 2015 | 2439 | 2015 |
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... New England Journal of Medicine 372 (16), 1500-1509, 2015 | 1688 | 2015 |
| Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management ES Stroes, PD Thompson, A Corsini, GD Vladutiu, FJ Raal, KK Ray, ... European heart journal 36 (17), 1012-1022, 2015 | 1529 | 2015 |
| Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European … J Boren, MJ Chapman, RM Krauss, CJ Packard, JF Bentzon, CJ Binder, ... European heart journal 41 (24), 2313-2330, 2020 | 1125 | 2020 |
| Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on … M Cuchel, E Bruckert, HN Ginsberg, FJ Raal, RD Santos, RA Hegele, ... European heart journal 35 (32), 2146-2157, 2014 | 1123 | 2014 |
| Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol KK Ray, RS Wright, D Kallend, W Koenig, LA Leiter, FJ Raal, JA Bisch, ... New England journal of medicine 382 (16), 1507-1519, 2020 | 1062 | 2020 |
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised … FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ... The Lancet 375 (9719), 998-1006, 2010 | 1042 | 2010 |
| Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment A Wiegman, SS Gidding, GF Watts, MJ Chapman, HN Ginsberg, M Cuchel, ... European heart journal 36 (36), 2425-2437, 2015 | 921 | 2015 |
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ... The Lancet 385 (9965), 331-340, 2015 | 880 | 2015 |
| Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial FJ Raal, N Honarpour, DJ Blom, GK Hovingh, F Xu, R Scott, ... The Lancet 385 (9965), 341-350, 2015 | 846 | 2015 |
| Low-density lipoprotein cholesterol–lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with … F Raal, R Scott, R Somaratne, I Bridges, G Li, SM Wasserman, EA Stein Circulation 126 (20), 2408-2417, 2012 | 677 | 2012 |
| The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association SS Gidding, M Ann Champagne, SD de Ferranti, J Defesche, MK Ito, ... Circulation 132 (22), 2167-2192, 2015 | 671 | 2015 |
| Inclisiran for the treatment of heterozygous familial hypercholesterolemia FJ Raal, D Kallend, KK Ray, T Turner, W Koenig, RS Wright, ... New England Journal of Medicine 382 (16), 1520-1530, 2020 | 652 | 2020 |
| The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management RA Hegele, HN Ginsberg, MJ Chapman, BG Nordestgaard, ... The lancet Diabetes & endocrinology 2 (8), 655-666, 2014 | 645 | 2014 |
| Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation GF Watts, S Gidding, AS Wierzbicki, PP Toth, R Alonso, WV Brown, ... International journal of cardiology 171 (3), 309-325, 2014 | 586 | 2014 |
| Evinacumab for homozygous familial hypercholesterolemia FJ Raal, RS Rosenson, LF Reeskamp, GK Hovingh, JJP Kastelein, ... New England Journal of Medicine 383 (8), 711-720, 2020 | 537 | 2020 |
| Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... N Engl J Med 372 (16), 1500-1509, 2015 | 469 | 2015 |
| Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment FJ Raal, RD Santos Atherosclerosis 223 (2), 262-268, 2012 | 441 | 2012 |
